- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
How Patient Descriptors Influence Racial Bias in the Electronic Health Record
On this episode of Managed Care Cast, we speak with Michael Sun, a medical student at the Pritzker School of Medicine at the University of Chicago, who served as first author of a Health Affairs study showing that race and bias were significantly associated with negative patient descriptors in the electronic health record.
Although racism and bias have been long documented issues affecting health equity, findings of a recent study published in Health Affairs indicates these issues may be more embedded in the US health care system than originally thought.
Examining electronic health records (EHRs) from an urban academic medical center, researchers found that negative descriptors were significantly more likely to appear in the records of Black patients compared with White patients. Other factors—such as insurance type, marriage status, and even the COVID-19 pandemic—influenced the odds of having this potentially stigmatizing language appear in a patient’s EHR.
On this episode of Managed Care Cast, we speak with the first author on the study, Michael Sun, a medical student at the Pritzker School of Medicine at the University of Chicago, on the findings, as well as the steps that can be taken to increase awareness among clinicians of these stigmatizing descriptors.
Listen above or through one of these podcast services:
Without IRA Fix, COA Warns Community Oncology Practices Will Shut Down
June 30th 2025Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL
June 30th 2025Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Read More
